Vireo Growth (VREOF) Long-Term Investments (2025 - 2026)

Vireo Growth (VREOF) posted Long-Term Investments of $6.0 million for Q1 2026, little changed sequentially from $6.0 million in Q4 2025.

Vireo Growth (VREOF) Long-Term Investments (2025 - 2026) Analysis & Trends

Vireo Growth has reported Long-Term Investments for 2 years, with the latest figure at $6.0 million in Q1 2026.

Quarterly Long-Term Investments changed N/A year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (changed N/A YoY) and the FY2025 annual result came in at $6.0 million, changed N/A from the prior year.
Long-Term Investments steadied at $6.0 million in Q1 2026 per VREOF's latest filing, from $6.0 million in the prior quarter.
Over five years, Long-Term Investments peaked at $13.1 million in Q2 2025 and troughed at $6.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	92.58 Mn
2	Teva Pharmaceutical Industries	43.15 Bn	39.49 Bn	2.15 Bn	-
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.58 Bn	22.78 Bn	5.10 Bn	63.23 Mn
5	United Therapeutics	22.16 Bn	19.50 Bn	683.80 Mn	1.14 Bn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.48 Bn	15.09 Bn	935.80 Mn	149.10 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-	60.00 Mn
10	Vireo Growth	491.44 Mn	349.14 Mn	95.30 Mn	11.70 Mn

Download Data